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Iam confident that readers of P&Tstruggle with the critical issue of med-ication adherence on a regular basis.
I am also sure that most of us are frus-
trated by our feeble attempts to improve
low rates of patient compliance, es -
pecially with medications needed for
chronic conditions. I am always on the
lookout for help in this area. An article in
the Archives of Internal Medicine1 might
just shed some light on our collective
conundru m.
Researchers at Emor y University
School of Medicine in Atlanta and at
McMaster University in Hamilton, On-
tario, Canada, completed an incredible
piece of scholarship: they reviewed every
randomized controlled trial published
from January 1967 to September 2004.
The articles covered interventions that
were intended to enhance adherence to
therapy with self-administered medica-
tions to treat chronic medical conditions.
Allow me to set the stage for this study,
outline the key components, and com-
ment on their findings.  
Summarizing the literature on com -
pliance with therapeutic regimens, the
investigat ors noted the dismal rates of
only 50% to 80% of patients who take their
medications as prescribed. Because
patients with chronic medical conditions
consume more of the domestic gross
national product (GNP) than ever before,
noncompliance has significant clinical
and economic implications. Other re-
searchers have noted that the problem of
adherence to therapy has been called the
“key mediator between good medical
practice and positive patient outcomes.”1
Yet we all know in our daily practice that
convincing patients to take a medication
for a chronic condition is an excruciat-
ingly difficult process, even for the best
primary care doctors who are often sad-
dled with this key responsibility. 
Can we gain any new insights from
this kind of comprehensive research
report ?  What does the current science
tell us? Are there any new take-home
messages for the troops on the front lines
of adherence?
The researchers evaluated more than
13,000 citations in the literature and then
reviewed nearly 1,000 of these articles in
full. They narrowed the search down to
about 38 articles, which they reviewed
according to specific criteria. The inves-
tigators “covered the waterfront” in the
published peer-reviewed literature of
adherence and compliance, and I trust
that their methodology was sound. 
They used a new statistical technique
called effect size. The effect size is calcu-
lated from information that is provided in
each article or that is directly obtaine d
from the original authors. It “compares
the difference in effect between study
groups,” divided by the standard devia-
tion of this difference, resultin g in stan-
dard deviation units.1
This measure is therefore independ-
ent of the method of measurement used
and allows an adequate comparison of
different interventions for all studies.
Effect size enables us to compare apples
with apples and oranges with oranges in
terms of which type of intervention im-
proves adherence and clinical outcomes.
After reviewing thousands of articles,
the authors created a taxonomy by divid -
ing essentially all of the papers into four
categories:
• Studies in the first category, called
“informational interventions,” de-
scribed cognitive strategies de-
signed primarily to educate and mo-
tivate patients by instructional
means. These interventions were
based on the concept that patients
who understand their condition and
its treatment will be more informed,
empowered, and likely to comply.
An example might be face-to-face,
oral, telephone, written, or audio -
visual education sessions.
• The second category, called “behav-
ioral interventions,” were strategies
designed to influence behavior
through shaping, reminding, or re-
warding desired behaviors. Exam-
ples might include skill-building
with the help of a health care pro -
fessional, automated pillboxes, cal-
endars, changes in packaging, or
other steps intended to remind
patients to take their medications.  
• The third categor y, “family and
socia l interventions,” involved creat-
ing a social support strategy, pro-
vided by family members or other
persons in other groups. Examples
might consist of support groups,
family counseling, and the like.
• The fourth category was a com-
bined intervention that could in-
clude features of some of the afore-
mentioned tools and procedures. 
In my view, so far so good; it sounds
like a pretty thorough classification
based on all of the available research
published over a 30-year period.
But now for the letdown—and why I
say, “Not again!” 
In this systematic review of all of the
randomized controlled trials designed to
enhance medication adherence over the
last 30 years, particularly in chronic med-
ical conditions, only a paltry 16 of the 37
trials that made it all the way to the final
analysis reported any consistent im-
provement in patient adherence. The
behaviora l interventions that reduced
dosing demands of individual therapies
consistently improved adherence with a
large effect size score, as previously
describe d. Apart from this limited find-
ing, other successful interventions usu-
ally contained multiple elements deliv-
ered over time.
So where does all of this leave us? 
Based on this literature review, the
most effective interventions were those
that simplified dosing demands and
involve d monitoring and feedback. Infor-
mational interventions, delivered over
multiple sessions, are probably also
effective but at a lower statistical rate.
For P&T committee members, this is
clearly an important, albeit disappoint-
ing, piece of scholarship. 
Where do we go from here?  
I think we need a totally new approach
to bring about patient adherence to and
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compliance with therapy for chronic
condition s. I challenge the pharmaceuti-
cal industry to support a nationwide
research agenda with appropriate re -
sources to conquer this vitally important
social challenge once and for all. I don’t
know about you, but I am tired of reading
comprehensive studies that show, over
and over again, that our ef for ts to
improve compliance have limited effects.
How can we continue to grow our expen-
sive formulary armamentarium—at the
same time knowing that few patients
actually comply with the drug regimens
we prescribe?
If you would like to learn more about
the Department of Health Policy’s work
in this area, you can obtain an educa-
tional CD on which we describe this
problem in more detail. You can request
a copy of “The Impact of Medication
Adherenc e” CD-ROM (MM1207) by call-
ing 1-888-825-5249.
As usual, I am interested in your views
on this subject and, of course, your opin-
ion of our special CD on compliance. You
can reach me at my e-mail address,
david.nash@jefferson.edu. 
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